2012 witnessed important developments for multiple sclerosis, including successful phase III trials of novel oral therapeutics and identification of the potassium channel KIR4.1 as an autoimmune target. Additionally, the lung was highlighted as an important site for immune-cell programming, and the relevance of a TNF receptor variant was clarified.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clozapine reduces infiltration into the CNS by targeting migration in experimental autoimmune encephalomyelitis
Journal of Neuroinflammation Open Access 12 February 2020
-
Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity
Scientific Reports Open Access 24 April 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
16 April 2013
In the version of this article initially published, the competing interests of F. Zipp were not included. The error has been corrected for the HTML and PDF versions of the article
References
Fox, R. J. et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367, 1087–1097 (2012).
Gold, R. et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367, 1098–1107 (2012).
Comi, G. et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 366, 1000–1009 (2012).
Linker, R. A. et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134, 678–692 (2011).
Albrecht, P. et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J. Neuroinflammation 9, 163 (2012).
Brück, W. & Wegner, C. Insight into the mechanism of laquinimod action. J. Neurol. Sci. 306, 173–179 (2011).
Schulze-Topphoff, U. et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS ONE 7, e33797 (2012).
Srivastava, R. et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N. Engl. J. Med. 367, 115–123 (2012).
Odoardi, F. et al. T cells become licensed in the lung to enter the central nervous system. Nature 488, 675–679 (2012).
Gregory, A. P. et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488, 508–511 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A. Methner declares associations with the following companies: Biogen Idec, Teva Pharmaceutical Industries. F. Zipp declares associations with the following companies: Biogen Idec, Merck/Serono, Novartis, Octapharma, ONO, Teva Pharmaceutical Industries. See the article online for full details of the relationships.
Rights and permissions
About this article
Cite this article
Methner, A., Zipp, F. Novel therapeutic options and drug targets in MS. Nat Rev Neurol 9, 72–73 (2013). https://doi.org/10.1038/nrneurol.2012.277
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.277
This article is cited by
-
Clozapine reduces infiltration into the CNS by targeting migration in experimental autoimmune encephalomyelitis
Journal of Neuroinflammation (2020)
-
Maladaptive cortical hyperactivity upon recovery from experimental autoimmune encephalomyelitis
Nature Neuroscience (2018)
-
Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity
Scientific Reports (2017)
-
Correction: Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS
Nature Reviews Neurology (2013)
